Company profile
Lingmed Ltd was founded in 2013 in Hong Kong, currently we have offices in Shanghai and Beijing. Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions
Lingmed's core products are healthcare intelligence databases, it covers global innovative assets & China market intelligence. Lingmed's Products and Services have been recognized by Fortune 500 multinational pharma and device companies as well as Chinese local big pharmacos
In addition, we provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports
Company strategy
Lingmed team has in depth of experience and knowledge about China healthcare market from Regulatory, Marketing, Sales and most important in deals making
Our strategy
To support China pharmaceutical / device /investment companies to make better decisions with the global leading healthcare databases and support our clients with in depth analysis and partnering to create more value for our clients in China and Europe
Our missions
Help pharmaceutical/device industry to improve productivities, make better decisions with intelligence databases
Bring Innovative healthcare products to China market to improve Chinese patients life quality and save lives
Our values
Efficiency, Passion, Integrity, Learning¸Team work
Company History
| Year | Milestone |
|---|---|
| 2022 | Lingmed signed exclusive BD agent agreement to support Adalta to find a China partner for their CAR-T related asset |
| 2022 | Lingmed hosted No. 11 Product and Company valuation workshop online |
| 2021 | Lingmed signed exclusive BD agent agreement to support Oncostellae to find a China partner for their gastrointestinal asset |
| 2021 | Lingmed signed exclusive BD agent agreement to support Nektr to find a China partner for their fungal infection asset |
| 2021 | Lingmed was responsible for an oncology-related licensing deal for a US biotech with Qilu Pharma for China |
| 2020 | Lingmed started “Biotech showcase” at the monthly webinar |
| 2020 | Linkedbio Partnering assets and initial analysis goes "live" online |
| 2019 | Lingmed monthly webinars gained public recognition in China and Europe |
| 2019 | Lingmed successfully organized Chinabio conference post gala dinner “After Party” at rooftop of Mint in Shanghai |
| 2018 | Lingmed opened its first oversea office in Munich, Germany |
| 2018 | Lingmed signed strategic partnership to further support China clients with Healthshare in Beijing |
| 2017 | Lingmed launched Linkedbio partnering services together with Pharmaplus to connect innovation between EU and China |
| 2017 | Lingmed acquired GBI's Source China EU market exclusive sales rights |
| 2016 | Lingmed launched add on services - Linkedbio analytical to support China clients with analysis and insights |
| 2015 | Lingmed acquired EvaluatePharma's China market exclusive sales rights |
| 2015 | Lingmed developed new sales processes with Advisor Sam |
| 2015-2018 | Lingmed attended JP Morgan, Bio Europe, China bio and local conferences and events to promote partners’ branded products |
| 2014 | Lingmed registered China legal entity |
| 2014 | Lingmed successfully organized the first valuation workshop in China |
| 2013 | Lingmed founded in Hong Kong |
| 2013 | Lingmed acquired Biotechgate from Switzerland China market exclusive sales rights |
| 2013 | Lingmed started collaborating with GBI on Source China domestic market sales |
Lingmed team events at a glance
Team dinner to discuss sales strategy
Valuation workshop working team in Shanghai
Team building – a day sailing on the lake
Speaking at domestic conference
Lingmed booth at conferences
Lingmed office
Lingmed at JP Morgan Conference
Team building dinner